Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

The FDA has endorsed plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific's experimental treatment for PAH.

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...